Status:
UNKNOWN
sFlt-1:PlGF Ratio in Gestational Diabetes: PREDICTION (PREeclampsia in DIabetiC gestaTION) Study
Lead Sponsor:
Azienda Ospedaliero, Universitaria Pisana
Conditions:
Gestational Diabetes
Gestational Hypertension
Eligibility:
FEMALE
18+ years
Brief Summary
The ratio of soluble fms-like tyrosine kinase 1 (sFlt-1) to placental growth factor (PlGF) is elevated in pregnant women before the clinical onset of preeclampsia and can be used to predict the preecl...
Detailed Description
Single center, observational, prospective study designed to validate a cutoff point of the sFlt-1:PlGF ratio for the prediction of the short-term absence or presence of preeclampsia in pregnancy compl...
Eligibility Criteria
Inclusion
- Age \> 18 years
- Diagnosis of GDM in the current pregnancy
Exclusion
- Twin pregnancies
- Pre-pregnancy diabetes (type 1 or type 2 diabetes)
- Gestosis already diagnosed during the current pregnancy
Key Trial Info
Start Date :
October 14 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2022
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT04877119
Start Date
October 14 2019
End Date
December 31 2022
Last Update
May 7 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Azienda Ospedaliero-Universitaria Pisana - U.O. Malattie Metaboliche e Diabetologia
Pisa, PI, Italy, 56124